Enhances binding of IGF2BP1 to N6-methyladenosine (m6A)-containing mRNAs, thereby contributing to increased mRNA stability (PubMed:32245947). Also increases the interaction of IGF2BP1 with RNA stabilizers ELAVL1/HUR, MATR3 and PABPC1, and increases the interaction of RNA stabilizers ELAVL1/HUR, MATR3 and PABPC1 with m6A-containing mRNAs (PubMed:32245947). Contributes to MYC stability by enhancing binding of IGF2BP1 to m6A-containing MYC mRNAs and increasing recruitment of RNA stabilizing proteins to m6A-containing MYC mRNAs (PubMed:32245947). Interacts with IGF2BP1 (via KH3 and KH4 domains); the interaction results in increased binding of IGF2BP1 to N6-methyladenosine (m6A)-containing mRNAs. Detected in colon (at protein level). Promotes colon cancer cell growth, colony formation, migration and invasion through enhanced stability of MYC (PubMed:32245947). Expressed in colorectal, breast, ovarian and nasopharyngeal cancer cells (PubMed:32245947). Higher levels are found in colon cancer cells than in adjacent nontumor tissue (PubMed:32245947). Could be the product of a pseudogene.